Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Payables (2016 - 2025)

Historic Payables for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $2.0 million.

  • Arcadia Biosciences' Payables rose 1908.98% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1908.98%. This contributed to the annual value of $2.1 million for FY2024, which is 1036.65% up from last year.
  • Latest data reveals that Arcadia Biosciences reported Payables of $2.0 million as of Q3 2025, which was up 1908.98% from $1.6 million recorded in Q2 2025.
  • Arcadia Biosciences' 5-year Payables high stood at $5.2 million for Q2 2021, and its period low was $1.6 million during Q2 2025.
  • Moreover, its 5-year median value for Payables was $2.7 million (2022), whereas its average is $2.8 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 4508.39% in 2022, then soared by 1908.98% in 2025.
  • Quarter analysis of 5 years shows Arcadia Biosciences' Payables stood at $3.6 million in 2021, then fell by 21.52% to $2.9 million in 2022, then crashed by 33.1% to $1.9 million in 2023, then grew by 10.37% to $2.1 million in 2024, then fell by 4.41% to $2.0 million in 2025.
  • Its Payables stands at $2.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.9 million for Q1 2025.